Phase II study of combination of the HyperCVAD regimen with dasatinib in patients with Philadelphia chromosome (Ph) or BCR-ABL positive acute lymphoblastic leukemia (ALL) and lymphoid blast phase chronic myeloid leukemia (CML-LB)

被引：6

作者：

Ravandi, Farhad ^{[1
]}

Thomas, Deborah ^{[1
]}

Kantarjian, Hagop ^{[1
]}

Faderl, Stefan ^{[1
]}

Koller, Charles ^{[1
]}

Brown, Devri ^{[1
]}

Garris, Rebecca ^{[1
]}

Borthakur, Gautam ^{[1
]}

Burger, Jan ^{[1
]}

Kebriaei, Partow ^{[1
]}

Jorgensen, Jeffrey ^{[1
]}

Jones, Dan ^{[1
]}

Cortes, Jorge ^{[1
]}

O'Brien, Susan ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

来源：

BLOOD | 2007年 / 110卷 / 11期

关键词：

D O I：

10.1182/blood.V110.11.2814.2814

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2814

引用

页码：828A / 828A

页数：1

共 50 条

[41] A phase 2 study of the combination of decitabine (DAC), venetoclax (VEN), and ponatinib in patients (Pts) with chronic myeloid leukemia (CML) in accelerated phase (AP)/myeloid blast phase (MBP) or Philadelphia-chromosome positive (Ph plus ) acute myeloid leukemia (AML)
Senapati, Jayastu
Ravandi, Farhad
Dinardo, Courtney Denton
Issa, Ghayas C.
Sasaki, Koji
Konopleva, Marina
Macaron, Walid
Nasr, Lewis Fady
Zoghbi, Marianne
Nasnas, Cedric Christophe
Pemmaraju, Naveen
Chien, Kelly Sharon
Ohanian, Maro
Jabbour, Elias
Maiti, Abhishek
Kantarjian, Hagop M.
Short, Nicholas James
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[42] Lineage involvement by BCR/ABL in Ph+ lymphoblastic leukemias: Chronic myelogenous leukemia presenting in lymphoid blast phase vs Ph+ acute lymphoblastic leukemia
Anastasi, J
Feng, J
Dickstein, JI
LeBeau, MM
Rubin, CM
Larson, RA
Rowley, JD
Vardiman, JW
LEUKEMIA, 1996, 10 (05) : 795 - 802
[43] Dynamics of Minimal Residual Leukemia After Combinations of the HyperCVAD Regimen with Imatinib or Dasatinib In Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia.
Ravandi, Farhad
Thomas, Deborah A.
O'Brien, Susan
Faderl, Stefan
Jorgensen, Jeffrey
Luthra, Rajyalakshmi
Jones, Dan
Garris, Rebecca
Cortes, Jorge E.
Kantarjian, Hagop
BLOOD, 2010, 116 (21) : 879 - 879
[44] A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia
J F Seymour
D W Kim
E Rubin
A Haregewoin
J Clark
P Watson
T Hughes
I Dufva
J L Jimenez
F-X Mahon
P Rousselot
J Cortes
G Martinelli
C Papayannidis
A Nagler
F J Giles
Blood Cancer Journal, 2014, 4 : e238 - e238
[45] A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia
Seymour, J. F.
Kim, D. W.
Rubin, E.
Haregewoin, A.
Clark, J.
Watson, P.
Hughes, T.
Dufva, I.
Jimenez, J. L.
Mahon, F-X
Rousselot, P.
Cortes, J.
Martinelli, G.
Papayannidis, Cristina
Nagler, A.
Giles, F. J.
BLOOD CANCER JOURNAL, 2014, 4 : e238 - e238
[46] Correlation of clinical response to BMS-354825 with BCR-ABL mutation status in imatinill-resistant patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-associated acute lymphoblastic leukemia (Ph plus ALL).
Shah, N
Sawyers, CL
Kantarjian, HMM
Donato, N
Nicoll, J
Cortes, J
Paquette, R
Huang, F
Clark, E
Talpaz, M
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 565S - 565S
[47] Combination of hyper-CVAD with imatinib mesylate (STI571) for Philadelphia (Ph)-positive adult acute lymphoblastic leukemia (ALL) or chronic myelogenous leukemia in lymphoid blast phase (CML-LBP).
Thomas, DA
Cortes, J
Giles, FJ
Faderl, S
O'Brien, S
Rios, MB
Issa, JP
García-Manero, G
Koller, C
Capdeville, R
Talpaz, M
Kantarjian, H
BLOOD, 2001, 98 (11) : 803A - 803A
[48] Low level mutations in the Bcr-Abl kinase domain may already be detected at diagnosis both in patients with Philadelphia-positive acute lymphoblastic leukemia and in patients with chronic phase chronic myeloid leukemia
Soverini, Simona
Gnani, Alessandra
Colarossi, Sabrina
Vitale, Antonella
Castagnetti, Fausto
Palandri, Francesca
Paolini, Stefania
Papayannidis, Cristina
Amabile, Marilina
Lacobucci, Ilaria
Poerio, Angela
Scotlandi, Katia
Lonetti, Annalisa
Mandelli, Franco
Baccarani, Michele
Foa, Robin
Martinelli, Giovanni
CANCER RESEARCH, 2009, 69
[49] Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia
Abaza, Yasmin
Kantarjian, Hagop
Alwash, Yasmin
Borthakur, Gautam
Champlin, Richard
Kadia, Tapan
Garcia-Manero, Guillermo
Daver, Naval
Ravandi, Farhad
Verstovsek, Srdan
Burger, Jan
Estrov, Zeev
Ohanian, Maro
Lim, Miranda
Pemmaraju, Naveen
Jabbour, Elias
Cortes, Jorge
AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (11) : 1288 - 1295
[50] A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial
Cortes, Jorge E.
Kim, Dong-Wook
Pinilla-Ibarz, Javier
le Coutre, Philipp
Paquette, Ron
Chuah, Charles
Nicolini, Franck E.
Apperley, Jane
Khoury, H. Jean
Talpaz, Moshe
DiPersio, John F.
DeAngelo, Daniel J.
Abruzzese, Elisabetta
Rea, Delphine
Baccarani, Michele
Muller, Martin C.
Gambacorti-Passerini, Carlo
Wong, Stephane
Lustgarten, Stephanie
Rivera, Victor M.
Clarkson, Tim
Turner, Christopher D.
Haluska, Frank G.
Guilhot, Francois
Deininger, Michael W.
Hochhaus, Andreas
Hughes, Timothy
Goldman, John M.
Shah, Neil
Kantarjian, Hagop M.
BLOOD, 2012, 120 (21)

← 1 2 3 4 5 →